ClinicalTrials.gov
public full text
Public Domain
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
To learn if MT-0169 is safe to give to patients with AML or T-ALL. The effects of this drug will also be studied.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma#1378656
- CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse#1281775
- MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease#881694
- A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma#834586
- "InDACtion" vs "3+7" Induction in AML#1186225
Record · ID 1397611
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive